Kellogg School of Management, Northwestern University, Evanston, Illinois, USA.
J Infect Dis. 2012 May 15;205 Suppl 2(Suppl 2):S181-90. doi: 10.1093/infdis/jis203. Epub 2012 Mar 7.
In recent years, there has been significant investment from both the private and public sectors in the development of diagnostic technologies to meet the need for human immunodeficiency virus (HIV) and tuberculosis testing in low-resource settings. Future investments should ensure that the most appropriate technologies are adopted in settings where they will have a sustainable impact. Achieving these aims requires the involvement of many stakeholders, as their needs, operational constraints, and priorities are often distinct. Here, we discuss these considerations from different perspectives representing those of various stakeholders involved in the development, introduction, and implementation of diagnostic tests. We also discuss some opportunities to address these considerations.
近年来，私营部门和公共部门都对诊断技术的开发进行了大量投资，以满足在资源匮乏环境中进行人类免疫缺陷病毒 (HIV) 和结核病检测的需求。未来的投资应确保在具有可持续影响的环境中采用最合适的技术。要实现这些目标，需要许多利益相关者的参与，因为他们的需求、运营限制和优先事项往往是不同的。在这里，我们从不同的角度来讨论这些问题，这些角度代表了参与诊断测试开发、引入和实施的各个利益相关者的观点。我们还讨论了一些解决这些问题的机会。
